Trial Profile
Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 Apr 2021 Study design changed from parallel to crossover.
- 30 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Jan 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.